Shots:

• BMS to make equity investment in Vedanta and Vedanta will evaluate Opdivo + VE800- for advanced or metastatic cancers
• The focus of the collaboration is to develop combination therapy and to research aspect of microbes in advanced or metastatic cancers
• Opdivo (nivolumab) is a programmed death-1 (PD-1) immune checkpoint inhibitor- approved to treat multiple cancer. VE800 is a bacterial consortium used for activating cytotoxic CD8+ T cells

Ref: Vedantabio | Image: BMS